Recent breakthroughs in immuno-oncology research translate into a paradigm shift with regards to attacking advancing cancer. The benefits of immuno-oncology have resulted in long-lasting tumor regression where surgery, radiotherapy, chemotherapy, and targeted therapy proved less effective.
There are several approaches within immuno-oncology research, including checkpoint inhibitor therapy, adoptive cell therapy (ACT), dendritic cell therapy, and cancer vaccine development. Figure 1 below depicts the adapted cancer-immunity cycle and the stages that can be impacted by discoveries within each research area. Thermo Fisher Scientific strives to provide the most innovative tools and educational assets to advance your immuno-oncology research. The categories below offer access to resources for each immuno-oncology research approach.